SpainSpain

“Independency Needed”

10.07.2004

Madrid - The Spanish government is preparing to challenge the recent lifting of the six year long EU moratorium on new GMO products. The EU's ban effectively ended in May this year (see EuroBiotechNews 1-2/04) when the EU Commission approved the genetically modified sweetcorn variety Bt-11. This happened after new EU rules on labelling and traceability had come into force.
Since 1998 Spain cultivated around half a million tons of GM maize, thereby becoming “Europe's GMO grain house” as Spain's socialist Environment Minister Cristina Narbona put in on June 22. She added that the government would now seek the advice of independent researchers. She questioned whether it was wise to continue the country's extensive cultivation of GMO crops, and went on to accuse the previous conservative government of authorising a massive extension of GMO crops without waiting for “independent” scientists to reach a definitive opinion: “We want to reinforce independent research in this area, and I underline the word independent, because in this country, where there is little scientific investigation, many researchers are privately financed by companies that want the research to have a specific conclusion,” Narbona said.
The new ministerial way to deal with GMO does not seem to be the official line of the recently elected new Spanish government. A day after Narbona's statements Miguel Sebastián, Director of the Economic Office from the President said during the presentation of the 4th ASEBIO Spanish Biotechnology Report (see page 37) that the government would support every R&D effort “to gain more productivity and competitiveness” in Europe.
Until the time of going to press the Environment Ministery was unavailable for EuroBiotechNews to get more specific information on the next steps Narbona is intending to take.

SpainSpain

01.10.2011

Granada – Alentia Biotech, a joint venture of Grupo Ferrer Internacional S.A. and Laboratorios Farmacéuticos Rovi S.A, has announced plans to construct a national production centre to supply the Spanish population with flu...

SpainSpain

01.10.2011

Lisbon – A Portuguese-American research team has discovered an association between a variant in the gene DZIP1 and Parkinson’s disease (PD). The collaboration brought André Valente from the Biocant Biotechnology Innovation Center...

SpainSpain

29.09.2011

Granada - Alentia Biotech, a joint venture of Spanish pharmaceuticals companies Laboratorios Farmaceuticos Rovi SA and Ferrer, will invest €92m in the construction of a flu vaccines plant in Granada. The annual production...

SpainSpain

23.09.2011

Madrid - Spain unveiled a grand alliance between all stakeholders in biomedicine to foster innovation in the sector. Minister of Science and Innovation, Cristina Garmendia, met the representatives of institutions, public research...

Italy, SpainSpain

18.08.2011

Vinaros – The Italian company Transactiva failed to start a field trial of a genetically modified rice variant in southeastern Spain. Although the National Commission on Biosafety had approved the field trial, the Committee on...

SpainSpain

09.08.2011

Madrid/Ingelheim – Pharmaceutical company Boehringer Ingelheim has cleared the way for Spanish rival Almirall and ended a long-standing patent squabble, although the reconciliation was not exactly voluntary. Behind the scenes,...

SpainSpain

13.06.2011

Madrid – Spain is working to establish itself as a European hotspot for bio­energy production. The country’s Abengoa Bioenergia Nuevas Tecnologias, a subsidiary of Abengoa Bioenergy, will lead an international consortium in the...

SpainSpain

11.06.2011

Madrid – Agendas, working committees and associations in Europe’s biotechnology sector are not hard to find. Now the spanking new Spanish Biotech Platform (launched in May) has to show if it is more than just another extension of...

SpainSpain

06.02.2011

Madrid – Noscira, a Madrid-based company looking for Alzheimer treatments in marine life forms, raised a19m in a private placement of 3.8 million shares at EUR5 to existing and new investors. The main stakeholder is Zeltia S.A,...

Displaying results 11 to 20 out of 181

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-spain/browse/1/article/independency-needed.html

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.08 SEK14.29%
  • PROTHENA PLC (IE)18.44 USD6.84%
  • WILEX (D)3.28 EUR5.47%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • HYBRIGENICS (F)1.71 EUR-8.56%

TOP

  • WILEX (D)3.28 EUR349.3%
  • SANTHERA (CH)69.50 CHF114.8%
  • ADDEX (CH)4.21 CHF92.2%

FLOP

  • MERCK KGAA (D)63.45 EUR-51.0%
  • THROMBOGENICS (B)8.55 EUR-47.3%
  • VERONA PHARMA (UK)1.12 GBP-46.2%

TOP

  • SANTHERA (CH)69.50 CHF3410.1%
  • GW PHARMACEUTICALS (UK)415.25 GBP756.2%
  • SKYEPHARMA PLC (UK)260.00 GBP314.3%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.2%
  • CYTOS (CH)0.27 CHF-92.1%
  • THROMBOGENICS (B)8.55 EUR-72.5%

No liability assumed, Date: 21.07.2014


Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events